Skip To Main Content
Barbara Sherry on Muck Rack

Barbara Sherry

As seen in: Nature, Science Magazine, The Journal of Biological Chemistry, The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival - Leukemia

|
By Gerardo Ferrer, Steven Allen, Shih-Shih Chen, Barbara Sherry
| Nature Verified
Patients with chronic lymphocytic leukemia (CLL) exhibit clinical findings suggesting an altered immune system, with an increased risk of infection and the development of other cancers and various autoimmune phenomena [1]. These associations are thought to be orchestrated in part by the interactions of leukemic cells with normal cells and elements in tissues, the latter referred to as the tumor microenvironment (TME). Notably, these interactions support the survival and expansion of CLL cells [2].
Open in Who Shared Issue with article?

Vagus nerve stimulation modulates distinct acetylcholine receptors on B cells and limits the germinal center response

|
By Bridget Waas, Virginia Byers Kraus, Liqi Li, Izumi Kurata-Sato, Yousef Al-Abed, Barbara Sherry, Stavros Zanos, Betty Diamond
| Science Magazine Verified
Research Article IMMUNOLOGY Izumi Kurata-Sato https://orcid.org/0000-0001-7815-9458, Ibrahim T.
Open in Who Shared Issue with article?

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors - Blood Cancer Journal

|
By John-Hanson Machado, Philippe Armand, Matthew S Davids, Barbara Sherry
| Nature Verified
Abstract PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity, despite promising efficacy and evidence that toxicity is associated with improved clinical outcomes. Prior phenotypic evaluation by CyTOF has identified increases in activated CD8 T cells with activation of Th17 T cells, as well as decreases in Tregs, particularly in patients with toxicity.
Open in Who Shared Issue with article?
See all 8 articles